Introduction
Prednisone at 1-2 mg/kg constitutes the present standard primary therapy for acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (HCT). However, complete response to this therapy is achieved in 40-50% of cases. (1) (2) (3) (4) Patients with glucocorticoid-refractory acute GVHD have limited response to available rescue therapies, and suffer inferior survival compared to those with glucocorticoidresponsive disease. (5) (6) (7) In the therapy of acute and chronic GVHD, HCT recipients suffer morbidity from glucocorticoid therapy. (8) (9) (10) (11) (12) The limited efficacy and associated toxicity of glucocorticoid therapy provide rationale for novel approaches in the therapy of acute GVHD.
Previous reports of combined therapy with glucocorticoids and additional immunosuppressive agents were disappointing. (13, 14) The combination of glucocorticoids and mycophenolate mofetil may promise improved GVHD control, (15) but this additional immunosuppression may enhance the risk of opportunistic infection and primary malignancy relapse after HCT. These and historical efforts have been based on the assumption that glucocorticoids constitute a necessary component of primary therapy for acute GVHD.
In a previous report, we suggested that sirolimus is active as sole primary therapy of acute GVHD.(16) This approach may allow the dual benefit of acute GVHD control and avoidance of systemic glucocorticoids. Given the antitumor activity of mTOR inhibitors demonstrated in allied literature, (17) (18) (19) (20) as well as evidence that its use as prophylaxis is associated with decreased lymphoma relapse post-transplant,(21) sirolimus may be a particularly attractive therapy for acute GVHD in those HCT recipients with high risk for relapse after HCT. As further evidence of the activity of sirolimus in the primary therapy of acute GVHD, we report an expanded cohort of HCT recipients treated with sirolimus as primary therapy for acute GVHD with extended follow up.
Design and Methods
Through retrospective review, 32 HCT recipients were identified who were treated with sirolimus as primary therapy of acute GVHD; biopsy confirmation of acute GVHD was present in 31 of 32 cases. In older patients, primary glucocorticoid therapy was avoided to spare toxicity, and in patients with active malignancy, sirolimus was preferred for its dual activity as immunosuppressant and anti-cancer drug. All patients received tacrolimus in combination with methotrexate (MTX) or mycophenolate mofetil (MMF) as acute GVHD prophylaxis. The target serum level of tacrolimus was decreased to 3-7 ng/ml while receiving concomitant sirolimus to mitigate the risk for thrombotic microangiopathy (TMA). Sirolimus was administered orally with a target serum level of 4-12 ng/ml by mass spectrometry or 5-14 ng/ml by the Architect assay (Abbott, Abbott Park, IL). In the absence of ongoing acute GVHD, tacrolimus was tapered with empiric dose reductions.
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Baseline characteristics were summarized with descriptive statistics. Established consensus criteria were utilized to score acute GVHD weekly from onset to sustained complete resolution or last follow up. 19 Complete response (CR) to sirolimus as primary therapy was defined as sustained complete resolution of acute GVHD manifestations for at least 4 weeks without the addition of systemic glucocorticoids or other systemic immunosuppressive agents. The association between CR to sirolimus alone and acute GVHD characteristics, including organ involvement and severity, was examined using logistic regression. Chronic GVHD was scored according to the proposed NIH consensus criteria. 20 Indication, initial dose, and duration of any glucocorticoid therapy was recorded and considered a failure of primary therapy with sirolimus. The cumulative incidence of disease relapse, non-relapse mortality, and cGVHD was estimated, accounting for competing risk. While sirolimus was utilized as primary therapy of acute GVHD outside of a prospective clinical trial, patients were adequately informed prior to therapy of the rationale for avoiding high dose steroid therapy, the potential risks associated with sirolimus, and the required monitoring to achieve and sustain therapeutic sirolimus levels. Sirolimus was utilized in this setting with patients adequately counseled on the anticipated risks, benefits and alternatives to this approach. All patients had signed an IRB-approved consent form indicating willingness to participate in long-term follow-up studies.
Results
Baseline characteristics of this series are summarized in Table 1 . The cohort is notable for advanced age (median 60, range 28-73, years), and for high risk malignancy, as 23
(72%) were not in remission at the time of HCT. Primary acute GVHD prophylaxis consisted of either tacrolimus plus methotrexate (n=29) or tacrolimus plus MMF (n=3).
Four patients with an HLA mismatched donor received additional Thymoglobulin 7.5 mg/kg ending on day -1. Patients were treated with sirolimus as the primary therapy for acute GVHD at median of 30 (range 15-106) days after HCT. Sirolimus was administered orally as a median loading dose of 6mg (range 2 to 9 mg), followed by maintenance dosing to sustain the desired target therapeutic levels. Therapeutic sirolimus levels were achieved in all cases, including patients with gastrointestinal involvement. When used in prophylaxis of acute GVHD, mycophenolate mofetil was continued with the initiation of sirolimus, however, tacrolimus was decreased to target a range between 3-7 ng/ml.
Sixteen (50%) patients achieved CR of acute GVHD following primary therapy with sirolimus without the addition of systemic glucocorticoids or any other systemic immunosuppressive agents (table 2) . Among these 16 patients who achieved complete resolution of acute GVHD with sirolimus alone, initial overall response (composite of partial and complete response) was achieved at median of 7 days (range 5-21 days) and complete response was achieved by a median of 14 days (range 5-28 days). In two of these cases, recurrent acute GVHD developed 7-12 weeks after initial CR; resolution of recurrent acute GVHD was achieved in both with the addition of 0.2 -0.5 mg/kg body weight of prednisone. In the remaining 16 cases, systemic glucocorticoids were initiated at a median of 9 days (range 2-28 days) after initiation of sirolimus with a prednisone-7 equivalent median dose of 0.5 (range 0.2-1) mg/kg, and 12 achieved resolution of acute GVHD ( Figure 1 ). Importantly, uniform criteria for initiation of systemic steroids after first line sirolimus therapy were not employed. Among these cases, prednisone was started after initial sirolimus therapy for persistent acute GVHD manifestations of unchanged severity in 6 cases (median 9 days from sirolimus initiation, range 2-19 days), grade progression in 6 cases (median 9 days from sirolimus initiation, range 2-16 days), in the setting of partial response in 2 cases (6-7 days after sirolimus initiation), and in 2 cases for recurrent acute GVHD within 4 weeks after initial complete response to sirolimus.
Four (12%) had persistent acute GVHD that was treated with mycophenolate mofetil. Of these four patients, one died following primary disease relapse, two died from nonrelapse causes (sepsis, and refractory acute GVHD with sepsis), and one is alive following resolution of acute GVHD and without relapse. On logistic regression analysis, neither acute GVHD severity nor organ involvement were significantly associated with complete response to sirolimus.
To further qualify our results, we performed a retrospective comparison of complete response rate following sirolimus primary therapy to CR following standard primary glucocorticoid therapy in a historical matched cohort treated at our center. These control subjects all had biopsy-confirmed acute GVHD, and were identified by matching to cases at each of the following variables: acute GVHD organ involvement and severity, donor relation, HLA matching, stem cell source, and acute GVHD prophylaxis agents utilized. All matched control subjects were treated with 1mg/kg of prednisone as primary therapy. Nineteen of these 32 subjects (59%) achieved complete remission, as compared to 16/32 (50%) of those treated with sirolimus primary therapy (Fisher's exact p value=0.47). These retrospective comparative data suggest comparable complete response rates achieved with sirolimus primary therapy as compared with standard 1mg/kg of prednisone.
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The cumulative incidence of chronic GVHD was 55% (95% CI 39-79%), with maximal NIH criteria global chronic GVHD score of mild in 5, moderate in 9, and severe in 3. With a median follow up for living patients of 16 months (6-26 months), one year overall survival (figure 2) was 56% (95% CI 38-74%), and one year relapse-free survival was 37% (95% CI 19-55%). Causes of death include the following: relapse (n=9), sepsis (n=3), veno-occlusive disease and CMV pneumonitis (n=1), cardiomyopathy (n=1), and chronic GVHD (n=1). The one year cumulative incidence of relapse was 37% (95% CI 23-60%), and the one year cumulative incidence of non-relapse mortality was 20% Importantly, these patients achieved the major therapeutic goal of acute GVHD resolution, while being spared toxicity of systemic glucocorticoids. An additional 38%
(total 88%) achieved complete resolution of acute GVHD with the addition of glucocorticoid doses largely less than 1mg/kg.
The low non-relapse mortality observed is encouraging in this group of older adults who largely received unrelated donor and mismatched unrelated donor allografts. This was particularly striking in those who achieved complete remission of aGVHD with sirolimus alone. The efficacy in aGVHD with this approach was also balanced by a favorable toxicity profile. Sirolimus was safely administered with tacrolimus with an overall low incidence of TMA, which was successfully managed with dose reduction or discontinuation of tacrolimus. This evidence further complements the durable efficacy of sirolimus in the primary therapy of acute GVHD.
Several limitations circumscribe these encouraging results. First, patients were treated according to physician discretion, introducing selection bias. This likely had significant impact on the acute GVHD severity distribution of the included patients. As well, uniform criteria for utilization of systemic glucocorticoids after first-line sirolimus therapy were not employed. Accordingly, patients received steroids for an array of indications, including persistent but stable manifestations, progressive severity, recurrent manifestations after initial complete response, and in the setting of partial response. As those with stable manifestations and partial response may have ultimately experienced complete response with sirolimus alone if additional time were allowed, the true failure rate or requirement for systemic glucocorticoids after primary sirolimus therapy is not clear from this data.
Additionally, while we did not detect significant differences in complete response rate according to organ involvement and acute GVHD severity, these analyses are necessarily limited by small numbers. In particular, the cohort does not include grade 4
aGVHD. The absence of this severity of acute GVHD in our series precludes any conclusion on the activity of sirolimus in primary therapy of grade 4 acute GVHD. While complete response rate would be anticipated to be less in grade 4 disease, this limited efficacy remains the unfortunate reality of available immune suppressive therapeutic agents. Another major concern is the potentially limited efficacy of sirolimus in advanced GI involvement given the exclusively oral formulation of the drug. While we have observed therapeutic serum levels of sirolimus and clinical response in cases with GI involvement, this effect may be undermined in the setting of vomiting and diarrhea of greater severity. Given this limitation, oral sirolimus may not be an effective primary intervention in an aGVHD syndrome manifesting large volume diarrhea. While the data reported here is encouraging, these limitations would be best addressed with the conduct of a prospective clinical trial of sirolimus as primary therapy for acute GVHD.
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